Cost-Effective Assessment Must Not Delay Patient Access: PhRMA’s HTA Chief

David L. Grainger, chair of PhRMA International HTA Task Force The planned introduction of a new cost-effective assessment scheme in Japan should not slow patient access to innovative drugs, David L. Grainger, chair of the Pharmaceutical Research and Manufacturers of...read more